Long-term cost-effectiveness of clopidogrel in STEMI patients

International Journal of Cardiology

Volumn 135, Issue 3, 2009, Pages 353-360

  Zhang, Zefeng ^a,b   Kolm, Paul ^e   Mosse, Frederique ^c   Jackson, Joseph ^d   Zhao, Liping ^b   Weintraub, William S ^e  

^a NANTONG UNIVERSITY   (China)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c SANOFI   (France)

^d BRISTOL MYERS SQUIBB   (United States)

^e CHRISTIANA CARE HEALTH SYSTEM   (United States)

Author keywords

Clopidogrel; Cost effectiveness; ST segment elevation myocardial infarction

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL;

ACUTE HEART INFARCTION; ADULT; ARTICLE; BLEEDING; CARDIAC PATIENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DEATH; DIAGNOSIS RELATED GROUP; DOUBLE BLIND PROCEDURE; DRUG COST; FEMALE; HOSPITAL COST; HOSPITALIZATION; HUMAN; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; MALE; MEDICARE; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL; REIMBURSEMENT; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STROKE;

AGED; ASPIRIN; COST-BENEFIT ANALYSIS; DECISION TREES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; TICLOPIDINE; TIME FACTORS; TREATMENT OUTCOME;

EID: 67349263400     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijcard.2008.04.011     Document Type: Article

References (19)

1. American Heart Association. Heart disease and stroke statistics - 2004 update (2003), American Heart Association, Dallas
2. Steinhubl S.R., Berger P.B., Mann III J.T., et al., CREDO Investigators. Clopidogrel for the Reduction of Events During Observation. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 288 (2002) 2411-2420
3. Yusuf S., Zhao F., Mehta S.R., et al., Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 345 (2001) 494-502
4. Beinart S.C., Kolm P., Veledar E., et al. Long-term cost effectiveness of early and sustained dual oral antiplatelet therapy with clopidogrel given for up to one year after percutaneous coronary intervention results: from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial. J Am Coll Cardiol 46 (2005) 761-769
5. Weintraub W.S., Mahoney E.M., Lamy A., et al., CURE Study Investigators. Long-term cost-effectiveness of clopidogrel given for up to one year in patients with acute coronary syndromes without ST-segment elevation. J Am Coll Cardiol 45 (2005) 838-845
6. Mahoney E.M., Mehta S., Yuan Y., et al., CURE Study Investigators. Long-term cost effectiveness of early and sustained clopidogrel therapy for up to 1 year in patients undergoing percutaneous coronary intervention after presenting with acute coronary syndromes without ST-segment elevation. Am Heart J 151 (2006) 219-227
7. Sabatine M.S., Cannon C.P., Gibson C.M., et al., CLARITY-TIMI 28 Investigators. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med 352 (2005) 1179-1189
8. CCS-2 collaborative group. Rationale, design, and organisation of the second Chinese cardiac study (CCS-2): a randomized trial of clopidogrel plus aspirin, and of metoprolol, among patients with suspected acute myocardial infarction. J Cardiovasc Risk 7 (2000) 435-441
9. COMMIT (ClOpidogrel and Metoprolol in Myocardial Infarction Trial) collaborative group. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 366 (2005) 1607-1621
10. Yusuf S., Mehta S.R., Zhao F., et al., Clopidogrel in Unstable angina to prevent Recurrent Events Trial Investigators. Early and late effects of clopidogrel in patients with acute coronary syndromes. Circulation 107 (2003) 966-972
11. Mitchell J., Burge R.T., Lee A.J., and McCall N.T. Per case prospective payment for episodes of hospital care (1995), US Department of Commerce National Technical Information Service, Springfield, VA
12. Peeters A., Mamun A.A., Willekens F., and Bonneux L. A cardiovascular life history. A life course analysis of the original Framingham Heart Study cohort. Eur Heart J 23 (2002) 458-466
13. Brauer C.A., Rosen A.B., Greenberg D., and Neumann P.J. Trends in the measurement of health utility in published cost-utility analyses. Value Health 9 (2006) 213-218
14. Zeymer U., Gitt A.K., Junger C., et al., Acute COronary Syndromes (ACOS) registry investigators. Effect of clopidogrel on 1-year mortality in hospital survivors of acute ST segment elevation myocardial infarction in clinical practice. Eur Heart J 27 (2006) 2661-2666
15. Weintraub W.S., Zhang Z., Mahoney E.M., et al. Cost-effectiveness of eplerenone compared with placebo in patients with myocardial infarction complicated by left ventricular dysfunction and heart failure. Circulation 111 (2005) 1106-1113
16. Chan P.S., Stein K., Chow T., Fendrick M., Bigger J.T., and Vijan S. Cost-effectiveness of a microvolt T-wave alternans screening strategy for implantable cardioverter-defibrillator placement in the MADIT-II-eligible population. J Am Coll Cardiol 48 (2006) 112-121
17. Eagle K.A., Lim M.J., Dabbous O.H., et al., GRACE Investigators. A validated prediction model for all forms of acute coronary syndrome: estimating the risk of 6-month postdischarge death in an international registry. JAMA 291 (2004) 2727-2733
18. Savonitto S., Ardissino D., Granger C.B., et al. Prognostic value of the admission electrocardiogram in acute coronary syndromes. JAMA 281 (1999) 707-713
19. Steg P.G., Lopez-Sendon J., Lopez de Sa E., et al., GRACE Investigators. External validity of clinical trials in acute myocardial infarction. Arch Intern Med 167 (2007) 68-73